Literature DB >> 30268177

End Stage Renal Disease Is Associated with Increased Mortality in Perforated Gastroduodenal Ulcers.

Daniel J Gross, Paul J Chung, Michael C Smith, Valery Roudnitsky, Antonio E Alfonso, Gainosuke Sugiyama.   

Abstract

Patients with end stage renal disease (ESRD) represent a growing subset of surgical candidates and ESRD status has been associated with increased morbidity and mortality in other operations. Using a national database, we examined outcomes and risk factors for patients presenting with perforated gastroduodenal ulcers undergoing omentopexy. We identified adult and emergent patients with perforated duodenal and gastroduodenal ulcers that underwent omentopexy using the 2005 to 2012 Nationwide Inpatient Sample. We identified patients with ESRD status and assessed comorbidity status using the Elixhauser-van Walraven score. Univariate and multivariable logistic regression analyses were performed. Inpatient mortality was the primary outcome. Six thousand five hundred and twenty-one patients were identified. Median age was 59.0 years, majority were male (55.56%), 79 (1.21%) patients had ESRD, 367 (5.63%) patients died during admission. Multivariable logistic regression showed age (OR 2.71, P < 0.0001), Elixhauser-van Walraven score (OR 2.69, P < 0.0001), and ESRD status (OR 3.88, P < 0.0001) as independent risk factors for mortality. ESRD was associated with increased mortality in patients undergoing omentopexy for perforated gastroduodenal ulcers. Future studies are necessary to identify methods to increase perioperative survival.

Entities:  

Mesh:

Year:  2018        PMID: 30268177

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  1 in total

1.  Clinical and financial impact of chronic kidney disease in emergency general surgery operations.

Authors:  Vishal Dobaria; Joseph Hadaya; Shannon Richardson; Cory Lee; Zachary Tran; Arjun Verma; Yas Sanaiha; Peyman Benharash
Journal:  Surg Open Sci       Date:  2022-06-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.